胃癌において Programmed death-ligand 1 は腫瘍悪牲度や予後の予測のための有用な血液マーカーである

• Material Type: 博士論文
• Title: 胃癌において Programmed death-ligand 1 は腫瘍悪牲度や予後の予測のための有用な血液マーカーである
• Author/Editor: 天辰, 仁彦
• Author Heading: 天辰, 仁彦 アマタツ, マサヒコ
• Publication, Distribution, etc.: Wiley
• Alternative Title: Programmed death-ligand 1 is a promising blood maker for predicting tumor progression and prognosis in patients with gastric cancer
• Degree grantor/type: 鹿児島大学
• Date Granted: 2020-03-12
• Dissertation Number: 甲総研第540号
• Degree Type: 博士(医学); Doctor of Philosophy in Medical Science
• Text Language Code: eng
• Subject Heading: gastric cancer; liquid biopsy; peripheral blood; prognosis; programmed death-ligand 1
• Target Audience: 一般
• Note (General): 博士論文全文, 博士論文要旨, 最終試験結果の要旨, 論文審査の要旨; Immune checkpoint inhibitor therapy has been clinically introduced for several malignancies, and its effectiveness has been confirmed by clinical trials. In particular, programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) are widely known as important immune checkpoint molecules associated with the mechanisms of immune escape by malignant tumor cells. In addition, liquid biopsy of blood specimens has the clinical benefit of providing a simple, repeatable sampling tool. Non-invasive liquid biopsy has recently been spotlighted as a promising approach to predicting tumor progression and prognosis. This study assessed the clinical significance of PD-L1 mRNA expression in blood specimens obtained from patients with gastric cancer. Peripheral blood specimens were collected before treatment from 124 patients with gastric cancer. The PD-L1 mRNA expression was evaluated by quantitative RT-PCR. Programmed death-ligand 1 mRNA expression was significantly higher in patients with advanced gastric cancer than in patients with early gastric cancer (P = .002). Moreover, PD-L1 expression correlated significantly with depth of tumor invasion, distant metastasis, and stage (P = .001, P < .001, and P < .001, respectively). Patients with high PD-L1 expression showed significantly poorer prognosis than those with low PD-L1 expression (P < .0001). Multivariate analysis indicated PD-L1 expression as an independent prognostic factor. Expression of PD-L1 in peripheral blood may offer an immunological predictor of tumor progression and disease outcome in patients with gastric cancer. Masahiko Amatatsu, Takaaki Arigami, Yoshikazu Uenosono, Shigehiro Yanagita, Yasuto Uchikado, Yuko Kijima, Hiroshi Kurahara, Yoshiaki Kita, Shinichiro Mori, Ken Sasaki, Itaru Omoto, Kosei Maemura, Sumiya Ishigami, Shoji Natsugoe Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer Cancer Science 2018 109(3) 814-820 https://doi.org/10.1111/cas.13508
• Format (IMT): application/pdf
• Access Restrictions: インターネット公開
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 鹿児島大学 : 鹿児島大学リポジトリ

Table of Contents

Result_Amatatsu_Masahiko_isk_540 other

Comments_Amatatsu_Masahiko_isk_540 other

Diss_天辰_仁彦_ISK540_2019 fulltext

Abstract_天辰_仁彦_4514810012_2019 abstract